John Gallagher Goes to Washington

Published in Government Relations on December 19, 2022

John Gallagher

On Dec. 14-15, John Gallagher, VP of VGM Government Relations, traveled to Capitol Hill in Washington D.C. making one last push for the industry before the end of the year. On this trip, John and AAHomecare’s Jay Witter joined forces to show our lawmakers a united front on behalf of the industry. Together they had many productive meetings and discussions with members of Congress and their staff over issues that the DME industry is facing.  

These congressional meetings included multiple members of Congress and their staff. Included were Sens. Crapo (R-ID), Wyden (D-OR), Grassley (R-IA), Cantwell (D-WA), and Ernst (R-IA). Meetings were also held with Reps. Smith (R-MO), Miller-Meeks (R-IA), Arrington (R-TX), Hinson (R-IA), Feenstra (R-IA), and McMorris-Rodgers (R-WA). 

Gallagher strongly requested support for the Senate extension of the CARES Act and House Bill H.R. 6641 (90/10 provision for CBA relief). He stressed the importance of including both in the Omnibus bill to support providers. John was told by an Energy and Commerce staffer that the CARES Act Extension is "in the mix," and there is still potential for H.R. 6641 as well. 

It was a very successful few days of meetings. We will keep everyone updated as the VGM Government Relations team continues to follow up with members of Congress after these meetings. We need your help to make sure the CARES Act Extension is included in the end-of-year package. It is important that everyone contacts their members of Congress.  

To contact your member of Congress, click here and enter your zip code. You can either send our message or you can call the D.C. Switchboard at (202)-224-3121. 

Special shoutout to Emily Harken, Director of Operations, VGM Government Relations, for working out the schedule and making all these meetings a possibility! 

From Our Experts

Proposed Rule Suggests Significant Change To Accreditation Process thumbnail Proposed Rule Suggests Significant Change To Accreditation Process The recently released proposed rule CMS-1828-P contains a significant change that could reshape how suppliers navigate accreditation. The rule proposes a major change that would require suppliers to be surveyed and reaccredited annually instead of the current three (3) year cadence. This proposal raises substantial questions about both operational feasibility and cost implications. August Of Action: Your Chance To Connect With Congress thumbnail August Of Action: Your Chance To Connect With Congress It's time to take advantage of August Of Action—a perfect opportunity to make your voice heard. Every summer, federal legislators return to their home states during the Congressional recess. While it gives them a break from Washington D.C., it's primarily a time for them to connect with constituents like you. HR1 Passes House, Advances to President Trump's Desk for Signature thumbnail HR1 Passes House, Advances to President Trump's Desk for Signature After extensive negotiations and partisan debate, the House has officially passed HR1, clearing the path for the bill to be signed into law by President Donald Trump. The legislation, which aims to reduce federal healthcare expenditures, contains several provisions that may impact the durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) industry. CMS files the Proposed Rule that sheds light on the next round of the Competitive Bidding Program thumbnail CMS files the Proposed Rule that sheds light on the next round of the Competitive Bidding Program On June 30, 2025, CMS filed the anticipated Proposed Rule that includes updates to the Competitive Bidding Program (CBP). Public comments are due 60 days from June 30, 2025. Below is a high-level summary of the rule. It is critical to note that, according to the Proposed Rule Fact Sheet dated June 30, 2025, CMS has stated that they have not announced the specific product categories they are bidding or the specific timeframe for the next competition. Those specifics will be forthcoming in a fu Senate Narrowly Passes HR1, Sending It Back to House for Final Approval thumbnail Senate Narrowly Passes HR1, Sending It Back to House for Final Approval President Donald Trump's sweeping legislative package, formally titled the One Big, Beautiful Bill Act, now referred to as HR1., cleared the Senate today in a dramatic 51–50 vote, with Vice President JD Vance casting the tie-breaking vote. The bill now returns to the House, where lawmakers must decide whether to adopt the Senate's revised version or negotiate further changes before it can reach the president's desk. Several Prominent Medicaid Provisions in Senate's Budget Bill Deemed in Violation of Byrd Rule thumbnail Several Prominent Medicaid Provisions in Senate's Budget Bill Deemed in Violation of Byrd Rule Senate Parliamentarian Elizabeth MacDonough advised this week that multiple Medicaid provisions in the Senate's reconciliation bill would violate Senate procedure by violating the Byrd Rule. The Byrd Rule is a Senate-specific procedural process that allows Senators to prevent or block inclusion of extraneous provisions in reconciliation bills. Other provisions are still under review. Evaluating the Value of a Payer Contract thumbnail Evaluating the Value of a Payer Contract In our last article, Key Payers Denied Your Application Citing Their Network Is Closed – Now What?, we discussed strategies for addressing payer contracting denials due to a closed network. As indicated, this process can be an extremely time-consuming exercise with no guarantees and mixed results. Below are a few things to consider as you evaluate whether a contract is worth the extra effort. Webinar: Webinar: "Navigating The New CMS Landscape: RADs, HMVs, and Supplier Survival" on June 25 at 1 p.m. CT. The Centers for Medicare & Medicaid Services (CMS) has released its final National Coverage Determination (NCD) for RADs and HMVs used in treating chronic respiratory failure due to COPD. While the rule potentially expands access to bilevel ST therapy (RADs), it also introduces complex compliance requirements, tighter usage criteria, and increased documentation burdens—without additional reimbursement.